SR 878
Alternative Names: SR-878Latest Information Update: 21 Oct 2024
Price :
$50 *
At a glance
- Originator SciRhom
- Class Anti-inflammatories; Antibodies; Antirheumatics; Monoclonal antibodies
- Mechanism of Action RHBDF2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 17 Oct 2024 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Austria (IV) (NCT06607484) (EudraCT-2023-507753-15-00)
- 09 Jul 2024 SciRhom plans a clinical trial (In volunteers) in Austria in the second half of 2024 (Parenteral)
- 12 Jun 2024 Austrian regulatory authorities approves clinical trial application for SR 878